Clinical Trials Directory

Trials / Completed

CompletedNCT00454233

A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects

A Randomized, Double Blind, Placebo and Active Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Potential Efficacy of a 12-Week Treatment With YM543 in Subjects With Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
97 (actual)
Sponsor
Astellas Pharma Inc · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the safety of YM543 in type 2 Diabetes Mellitus patients and to investigate whether this study drug is effective in these patients

Conditions

Interventions

TypeNameDescription
DRUGYM543Oral
DRUGMetforminOral
DRUGPlacebooral

Timeline

Start date
2007-02-01
Primary completion
2008-06-01
Completion
2008-06-01
First posted
2007-03-30
Last updated
2008-10-16

Locations

6 sites across 1 country: Russia

Source: ClinicalTrials.gov record NCT00454233. Inclusion in this directory is not an endorsement.